Logo image of GMDA

GAMIDA CELL LTD (GMDA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GMDA - IL0011552663 - Common Stock

0.0327 USD
-0.01 (-18.25%)
Last: 4/5/2024, 8:00:00 PM
0.032 USD
0 (-2.14%)
After Hours: 4/5/2024, 8:00:00 PM
Fundamental Rating

2

Overall GMDA gets a fundamental rating of 2 out of 10. We evaluated GMDA against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of GMDA have multiple concerns. While showing a medium growth rate, GMDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GMDA had negative earnings in the past year.
In the past year GMDA has reported a negative cash flow from operations.
In the past 5 years GMDA always reported negative net income.
GMDA had a negative operating cash flow in each of the past 5 years.
GMDA Yearly Net Income VS EBIT VS OCF VS FCFGMDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

GMDA has a worse Return On Assets (-61.65%) than 60.48% of its industry peers.
Industry RankSector Rank
ROA -61.65%
ROE N/A
ROIC N/A
ROA(3y)-61.87%
ROA(5y)-54.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GMDA Yearly ROA, ROE, ROICGMDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K 2K

1.3 Margins

The Gross Margin of GMDA (18.53%) is better than 75.47% of its industry peers.
GMDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GMDA Yearly Profit, Operating, Gross MarginsGMDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

GMDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GMDA has more shares outstanding
GMDA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GMDA has a worse debt to assets ratio.
GMDA Yearly Shares OutstandingGMDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
GMDA Yearly Total Debt VS Total AssetsGMDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -8.53, we must say that GMDA is in the distress zone and has some risk of bankruptcy.
GMDA has a worse Altman-Z score (-8.53) than 74.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.53
ROIC/WACCN/A
WACC5.78%
GMDA Yearly LT Debt VS Equity VS FCFGMDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

GMDA has a Current Ratio of 2.16. This indicates that GMDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.16, GMDA is doing worse than 75.98% of the companies in the same industry.
A Quick Ratio of 2.09 indicates that GMDA has no problem at all paying its short term obligations.
The Quick ratio of GMDA (2.09) is worse than 75.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.09
GMDA Yearly Current Assets VS Current LiabilitesGMDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.19% over the past year.
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 50.79% on average over the next years. This is a very strong growth
Based on estimates for the next years, GMDA will show a very strong growth in Revenue. The Revenue will grow by 182.44% on average per year.
EPS Next Y9.37%
EPS Next 2Y50.84%
EPS Next 3Y51.21%
EPS Next 5Y50.79%
Revenue Next Year808.75%
Revenue Next 2Y935.67%
Revenue Next 3Y499.3%
Revenue Next 5Y182.44%

3.3 Evolution

GMDA Yearly Revenue VS EstimatesGMDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
GMDA Yearly EPS VS EstimatesGMDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GMDA. In the last year negative earnings were reported.
Also next year GMDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GMDA Price Earnings VS Forward Price EarningsGMDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GMDA Per share dataGMDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as GMDA's earnings are expected to grow with 51.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.84%
EPS Next 3Y51.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GMDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GAMIDA CELL LTD

NASDAQ:GMDA (4/5/2024, 8:00:00 PM)

After market: 0.032 0 (-2.14%)

0.0327

-0.01 (-18.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2024-03-27/bmo
Earnings (Next)05-07 2024-05-07/amc
Inst Owners0.24%
Inst Owner Change0%
Ins Owners3.15%
Ins Owner Change0%
Market Cap4.34M
Revenue(TTM)1.78M
Net Income(TTM)-63.00M
Analysts80
Price Target4.42 (13416.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84.15%
Min EPS beat(2)74.12%
Max EPS beat(2)94.18%
EPS beat(4)3
Avg EPS beat(4)28.83%
Min EPS beat(4)-56.46%
Max EPS beat(4)94.18%
EPS beat(8)5
Avg EPS beat(8)12.83%
EPS beat(12)8
Avg EPS beat(12)12.1%
EPS beat(16)10
Avg EPS beat(16)4.74%
Revenue beat(2)1
Avg Revenue beat(2)-34.95%
Min Revenue beat(2)-72.29%
Max Revenue beat(2)2.4%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)18.03%
Revenue NY rev (3m)17.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.01
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.53%
FCFM N/A
ROA(3y)-61.87%
ROA(5y)-54.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.41%
Cap/Sales 60.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.09
Altman-Z -8.53
F-Score4
WACC5.78%
ROIC/WACCN/A
Cap/Depr(3y)1665.53%
Cap/Depr(5y)1683.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y9.37%
EPS Next 2Y50.84%
EPS Next 3Y51.21%
EPS Next 5Y50.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year808.75%
Revenue Next 2Y935.67%
Revenue Next 3Y499.3%
Revenue Next 5Y182.44%
EBIT growth 1Y3.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.35%
OCF growth 3YN/A
OCF growth 5YN/A

GAMIDA CELL LTD / GMDA FAQ

Can you provide the ChartMill fundamental rating for GAMIDA CELL LTD?

ChartMill assigns a fundamental rating of 2 / 10 to GMDA.


What is the valuation status for GMDA stock?

ChartMill assigns a valuation rating of 1 / 10 to GAMIDA CELL LTD (GMDA). This can be considered as Overvalued.


Can you provide the profitability details for GAMIDA CELL LTD?

GAMIDA CELL LTD (GMDA) has a profitability rating of 1 / 10.


What is the financial health of GAMIDA CELL LTD (GMDA) stock?

The financial health rating of GAMIDA CELL LTD (GMDA) is 2 / 10.